Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2019
Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 171 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed for Intermediate/High Risk Childhood B-cell ALL
Chinese Children's Cancer Group-2025 Protocol for Newly Diagnosed Low Risk Childhood B-cell Acute Lymphoblastic Leukemia
Who cites it
171 citing papers in PubMed, 6 syntheses or guidelines pooled it, 258 citations in OpenAlex.
- American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults.Blood advances · 2026Guideline
- Pediatric-inspired regimens and HSCT for adolescents and young adults with acute lymphoblastic leukemia.Blood advances · 2026Pooled it
- Meta-analysis of altered gray matter volume in acute lymphoblastic leukemia patients' postchemotherapy via the AES-SDM.European journal of medical research · 2025Pooled it
- Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action.Leukemia · 2025Pooled it
- Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia.Advances in therapy · 2023Pooled it
- PEG-asparaginase treatment regimens for acute lymphoblastic leukaemia in children: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.Annals of hematology · 2026Trial
- JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Trial
- Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 study.Haematologica · 2023Trial
- Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia.Leukemia · 2023Trial
- Trial
- Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.Cancer chemotherapy and pharmacology · 2021Trial
- Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial.The Lancet. Oncology · 2021Trial
- Dosing-related saturation of toxicity and accelerated drug clearance with pegaspargase treatment.Blood · 2020Trial
- Prospective randomized trial of interventions for vincristine-related neuropathic pain.Pediatric blood & cancer · 2020Trial
- Combined Early Steroid Response and MRD Improve Risk Stratification in Pediatric Acute Lymphoblastic Leukemia: The CCCG-ALL-2015 Study.European journal of haematology · 2026Article
- Traumatic lumbar puncture at diagnosis in children and adolescents with acute lymphoblastic leukemia.Leukemia · 2026Article
- Lnc-TIM3 promotes acute lymphoblastic leukemia progression through miR-5094-mediated regulation of TIM3.Translational cancer research · 2026Article
- Measurable residual disease detected by next-generation sequencing in T-cell acute lymphoblastic leukemia.Nature communications · 2026Article
111 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeDespite contemporary treatment, up to 10% of children with acute lymphoblastic leukemia still experience relapse. We evaluated whether a higher dosage of PEG-asparaginase and early intensification of triple intrathecal therapy would improve systemic and CNS control. PATIENTS AND
methodsBetween 2007 and 2017, 598 consecutive patients age 0 to 18 years received risk-directed chemotherapy without prophylactic cranial irradiation in the St Jude Total Therapy Study 16. Patients were randomly assigned to receive PEG-asparaginase 3,500 U/m
resultsThe 5-year event-free survival and overall survival rates for the 598 patients were 88.2% (95% CI, 84.9% to 91.5%) and 94.1% (95% CI, 91.7% to 96.5%), respectively. Cumulative risk of any-isolated or combined-CNS relapse was 1.5% (95% CI, 0.5% to 2.5%). Higher doses of PEG-asparaginase did not affect treatment outcome. T-cell phenotype was the only independent risk factor for any CNS relapse (hazard ratio, 5.15; 95% CI, 1.3 to 20.6;
conclusionHigher doses of PEG-asparaginase failed to improve outcome, but additional intrathecal therapy during early induction seemed to contribute to improved CNS control without excessive toxicity for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.